Boston Scientific Corporation $BSX Shares Acquired by Corient Private Wealth LP

Key Points

• Corient Private Wealth increased its Boston Scientific stake by 25.3% in the second quarter, adding 47,125 shares to reach 233,728 shares valued at approximately $9.98 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific reported quarterly EPS of $0.86, exceeding estimates of $0.83, while revenue rose 7.5% year over year to $5.44 billion. The company guided for third-quarter 2026 EPS of $0.80–$0.82 and full-year EPS of $3.28–$3.32.
• Analysts maintain a generally positive view, with 24 Buy, five Hold, and two Sell ratings and a consensus target price of $71.46. CEO Michael F. Mahoney and a company director also purchased shares, contributing to nearly $9.4 million in insider buying over the past three months.

Corient Private Wealth LP increased its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 25.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 233,728 shares of the medical equipment provider's stock after acquiring an additional 47,125 shares during the quarter. Corient Private Wealth LP's holdings in Boston Scientific were worth $9,976,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Renaissance Group LLC purchased a new position in shares of Boston Scientific during the fourth quarter worth approximately $28,064,000. Perigon Wealth Management LLC purchased a new stake in Boston Scientific in the 2nd quarter valued at $883,000. Y Intercept Hong Kong Ltd raised its position in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider's stock valued at $47,816,000 after purchasing an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in Boston Scientific during the 2nd quarter worth $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab boosted its stake in Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider's stock worth $13,659,000 after purchasing an additional 28,961 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 0.2%

Shares of NYSE:BSX opened at $43.97 on Thursday. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm's 50-day simple moving average is $46.96 and its 200-day simple moving average is $53.88. The company has a market cap of $63.72 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 1.02 and a beta of 0.57.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm's revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 3.29 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on BSX shares. Oppenheimer dropped their price objective on shares of Boston Scientific from $90.00 to $85.00 and set an "outperform" rating on the stock in a research note on Monday, July 27th. Jefferies Financial Group decreased their target price on shares of Boston Scientific from $100.00 to $67.00 and set a "buy" rating for the company in a research note on Wednesday, June 24th. Canaccord Genuity Group lowered their price target on Boston Scientific from $70.00 to $66.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. UBS Group dropped their price target on Boston Scientific from $74.00 to $67.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Finally, Raymond James Financial reaffirmed an "outperform" rating and set a $57.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $71.46.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David C. Habiger acquired 2,100 shares of the business's stock in a transaction on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director directly owned 17,160 shares of the company's stock, valued at $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company's stock.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.